Dr. Reddy's Laboratories has received the Establishment Inspection Report (EIR) from the US Food & Drug Administration (USFDA) for its Formulations Manufacturing Facility at Vishakhapatnam.

The USFDA has explained that the inspection has not closed, and the site's status remains unchanged, but that USFDA has released the EIR in order to be transparent about its regulatory process. The company is planning to request a re-inspection in 2018 after further discussion on scheduling with USFDA.

Shares of the company gained Rs 73, or 3.21%, to trade at Rs 2,350.30. The total volume of shares traded was 150,479 at the BSE (12.33 p.m., Tuesday).